Delta-Fly Pharma, Inc. (4598.T)
Tokyo · JPY · Healthcare · Biotechnology
¥72 (-1.37%) as of
Key statistics
- Market cap
- 1.02B
- Forward P/E
- -3.89
- EPS (TTM)
- -140.45
- Dividend yield
- 0.00%
- 52-week range
- 68.00 – 700.00
- Beta
- -0.78
- Profit margin
- 0.00%
- Volume
- 308.70k
About Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase II/III clinical trials for the treatment of solid cancer; DFP-11207, which in phase I/II clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Tokushima, Japan
- Employees
- 12
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.